141 related articles for article (PubMed ID: 12859744)
1. p53 alterations in porokeratosis.
Arranz-Salas I; Sanz-Trelles A; Ojeda DB
J Cutan Pathol; 2003 Aug; 30(7):455-8. PubMed ID: 12859744
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutation analysis in porokeratosis and porokeratosis-associated squamous cell carcinoma.
Ninomiya Y; Urano Y; Yoshimoto K; Iwahana H; Sasaki S; Arase S; Itakura M
J Dermatol Sci; 1997 Mar; 14(3):173-8. PubMed ID: 9138474
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of p53 tumor suppressor protein in porokeratosis.
Urano Y; Sasaki S; Ninomiya Y; Oura H; Arase S
J Dermatol; 1996 May; 23(5):365-8. PubMed ID: 8675831
[TBL] [Abstract][Full Text] [Related]
4. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H
Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937
[TBL] [Abstract][Full Text] [Related]
5. Disseminated porokeratosis with fatal metastatic squamous cell carcinoma: an additional case of "malignant disseminated porokeratosis".
Rongioletti F; Rebora A
Am J Dermatopathol; 2002 Apr; 24(2):144-8. PubMed ID: 11979075
[TBL] [Abstract][Full Text] [Related]
6. Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: correlation with human papillomaviruses?
O'Connor DP; Kay EW; Leader M; Murphy GM; Atkins GJ; Mabruk MJ
Diagn Mol Pathol; 2001 Sep; 10(3):190-9. PubMed ID: 11552722
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of p53 tumor suppressor protein in porokeratosis.
Magee JW; McCalmont TH; LeBoit PE
Arch Dermatol; 1994 Feb; 130(2):187-90. PubMed ID: 8304757
[TBL] [Abstract][Full Text] [Related]
8. Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis.
Einspahr JG; Alberts DS; Warneke JA; Bozzo P; Basye J; Grogan TM; Nelson MA; Bowden GT
Neoplasia; 1999 Nov; 1(5):468-75. PubMed ID: 10933063
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of p53 is associated with tumour progression in cutaneous lesions of renal allograft recipients.
Stark LA; Arends MJ; McLaren KM; Benton EC; Shahidullah H; Hunter JA; Bird CC
Br J Cancer; 1994 Oct; 70(4):662-7. PubMed ID: 7917913
[TBL] [Abstract][Full Text] [Related]
10. p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study of 12 cases.
Marrogi AJ; Khan MA; Vonderheid EC; Wood GS; McBurney E
J Cutan Pathol; 1999 Sep; 26(8):369-78. PubMed ID: 10551408
[TBL] [Abstract][Full Text] [Related]
11. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan.
Hsu CH; Yang SA; Wang JY; Yu HS; Lin SR
Br J Cancer; 1999 Jun; 80(7):1080-6. PubMed ID: 10362120
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutations in squamous cell carcinoma occurring in scars: comparison with p53 protein immunoreactivity.
Sakatani S; Kusakabe H; Kiyokane K; Suzuki K
Am J Dermatopathol; 1998 Oct; 20(5):463-7. PubMed ID: 9790106
[TBL] [Abstract][Full Text] [Related]
13. Chronic ultraviolet exposure-induced p53 gene alterations in Sencar mouse skin carcinogenesis model.
Tong Y; Smith MA; Tucker SB
J Toxicol Environ Health; 1997 Jun; 51(3):219-34. PubMed ID: 9183379
[TBL] [Abstract][Full Text] [Related]
14. Mutation spectra of epidermal p53 clones adjacent to basal cell carcinoma and squamous cell carcinoma.
Bäckvall H; Strömberg S; Gustafsson A; Asplund A; Sivertsson A; Lundeberg J; Ponten F
Exp Dermatol; 2004 Oct; 13(10):643-50. PubMed ID: 15447725
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
Kim KH; Park EJ; Seo YJ; Cho HS; Kim CW; Kim KJ; Park HR
J Dermatol; 2006 May; 33(5):319-25. PubMed ID: 16700663
[TBL] [Abstract][Full Text] [Related]
16. Analysis of p53 tumor suppressor gene, H-ras protooncogene and proliferating cell nuclear antigen (PCNA) in squamous cell carcinomas of HRA/Skh mice following exposure to 8-methoxypsoralen (8-MOP) and UVA radiation (PUVA therapy).
Lambertini L; Surin K; Ton TV; Clayton N; Dunnick JK; Kim Y; Hong HH; Devereux TR; Sills RC
Toxicol Pathol; 2005; 33(2):292-9. PubMed ID: 15902973
[TBL] [Abstract][Full Text] [Related]
17. p53 gene mutations in skin cancers with underlying disorders.
Kanekura T; Kanzaki T; Kanekura S; Kawahara K; Nakashima T; Kitajima I; Maruyama I
J Dermatol Sci; 1995 May; 9(3):209-14. PubMed ID: 8664219
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the ultraviolet B and X-ray response of primary cultured epidermal cells from patients with disseminated superficial actinic porokeratosis.
D'Errico M; Teson M; Calcagnile A; Corona R; Didona B; Meschini R; Zambruno G; Dogliotti E
Br J Dermatol; 2004 Jan; 150(1):47-55. PubMed ID: 14746616
[TBL] [Abstract][Full Text] [Related]
19. The density of epidermal p53 clones is higher adjacent to squamous cell carcinoma in comparison with basal cell carcinoma.
Bäckvall H; Wolf O; Hermelin H; Weitzberg E; Pontén F
Br J Dermatol; 2004 Feb; 150(2):259-66. PubMed ID: 14996096
[TBL] [Abstract][Full Text] [Related]
20. Retinoblastoma gene expression in human non-melanoma skin cancer.
Edwards MJ; Thomas RC; Wong YL
J Cutan Pathol; 2003 Sep; 30(8):479-85. PubMed ID: 12950498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
